House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Obstetrics & gynaecology

Diabetes in pregnancy: management from preconception to the postnatal period

NICE · 2020 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This NICE guideline (NG3) covers care for women with pre-existing type 1 or type 2 diabetes and for women with gestational diabetes, from preconception planning through antenatal, intrapartum, neonatal and postnatal care. Topics include: - preconception glycaemic targets, folic acid, medicine review, and retinal and renal assessment - risk-based OGTT testing, diagnostic thresholds and stepwise treatment for gestational diabetes - antenatal glucose monitoring and targets, continuous glucose monitoring (updated 2020), ketone testing and fetal surveillance - timing of birth and intrapartum glucose control - prevention of neonatal hypoglycaemia - postnatal diabetes testing after gestational diabetes Each recommendation carries its year of issue or amendment.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Preconception care

  • Advise women planning pregnancy to take folic acid 5 mg/day until 12 weeks of gestation to lower the risk of neural tube defects. [1]
  • Offer HbA1c measurement up to monthly before conception. Advise aiming for HbA1c below 48 mmol/mol (6.5%) where this is achievable without problematic hypoglycaemia. Strongly advise against pregnancy while HbA1c is above 86 mmol/mol (10%). [1]
  • Metformin may be advised as an adjunct or alternative to insulin before and during pregnancy when likely benefits outweigh potential harm. All other oral glucose-lowering agents should be stopped before pregnancy and replaced with insulin. NPH (isophane) insulin is the first-choice long-acting insulin. Continuing detemir or glargine can be considered when control was already good before pregnancy. Detemir (Levemir) supply is expected to end in December 2026. [1]
  • Stop ACE inhibitors, angiotensin-II receptor antagonists and statins before conception or as soon as pregnancy is confirmed. Switch to antihypertensives suitable in pregnancy. [1]
  • Offer retinal assessment at the first preconception appointment unless one was done in the last 6 months. Advise deferring rapid glucose optimisation until retinal assessment and treatment are complete. [1]
  • Offer renal assessment, including albuminuria, before contraception is stopped. Consider nephrology referral if any of the following apply: - serum creatinine is 120 micromol/litre or more - urinary albumin:creatinine ratio is greater than 30 mg/mmol - eGFR is less than 45 ml/minute/1.73 m2 [1]

Gestational diabetes: risk assessment, testing and diagnosis

  • At booking, check for these risk factors and offer testing if any is present: - BMI of 30 kg/m2 or over - previous macrosomic baby of 4.5 kg or more - previous gestational diabetes - first-degree relative with diabetes - ethnicity with high diabetes prevalence Do not use fasting or random glucose, HbA1c, glucose challenge test or urinalysis for risk assessment. [1]
  • Test at-risk women with a 75-g 2-hour OGTT. - After previous gestational diabetes: offer early self-monitoring, or an OGTT as soon as possible after booking with a repeat at 24 to 28 weeks if normal. - Other risk factors: offer an OGTT at 24 to 28 weeks. [1]
  • Diagnose gestational diabetes if fasting plasma glucose is 5.6 mmol/litre or above, or 2-hour plasma glucose is 7.8 mmol/litre or above. After diagnosis: - offer joint diabetes and antenatal clinic review within 1 week - inform the primary care team - measure HbA1c to identify possible pre-existing type 2 diabetes [1]

Gestational diabetes: treatment

  • Refer all women with gestational diabetes to a dietitian. If fasting glucose at diagnosis is below 7 mmol/litre, offer a trial of diet and exercise changes, then step up as needed: - targets unmet within 1 to 2 weeks: offer metformin - metformin contraindicated or unacceptable: offer insulin - targets unmet on metformin: add insulin [1]
  • If fasting glucose at diagnosis is 7.0 mmol/litre or above, offer immediate insulin (with or without metformin) plus diet and exercise changes. Consider the same approach at 6.0 to 6.9 mmol/litre when there are complications such as macrosomia or hydramnios. [1]

Antenatal care for all women with diabetes

  • Advise daily testing of fasting, pre-meal, 1-hour post-meal and bedtime glucose for pregnant women with: - type 1 diabetes - type 2 or gestational diabetes on multiple daily injections Pregnant women with type 2 or gestational diabetes test fasting and 1-hour post-meal levels daily if they are managed by any of: - diet and exercise changes alone - oral therapy - single-dose intermediate- or long-acting insulin [1]
  • Capillary plasma glucose targets apply to any form of diabetes, if achievable without problematic hypoglycaemia. Keep levels below: - fasting: 5.3 mmol/litre - 1 hour after meals: 7.8 mmol/litre, or 2 hours after meals: 6.4 mmol/litre Women taking insulin should stay above 4 mmol/litre. [1]
  • Offer real-time CGM to all pregnant women with type 1 diabetes. Offer flash (intermittently scanned) CGM to those unable to use rtCGM or who clearly prefer it. Consider rtCGM for insulin-treated women without type 1 diabetes who have either: - problematic severe hypoglycaemia, or - concerning unstable glucose despite optimisation efforts [1]
  • Offer blood ketone strips and a meter to pregnant women with type 1 diabetes. Test urgently for ketonaemia in any pregnant woman with diabetes who is hyperglycaemic or unwell. Admit suspected diabetic ketoacidosis immediately to level 2 critical care with combined medical and obstetric care. [1]
  • For pre-existing diabetes, after the first antenatal clinic visit: - offer retinal imaging with tropicamide mydriasis, unless assessed in the last 3 months - offer an extra assessment at 16 to 20 weeks if retinopathy is present - offer another assessment at 28 weeks Retinopathy does not contraindicate rapid glucose optimisation when early-pregnancy HbA1c is high. [1]
  • Arrange renal assessment at first pregnancy contact for pre-existing diabetes unless done within 3 months. Consider nephrology referral if any of the following apply: - creatinine is 120 micromol/litre or more - albumin:creatinine ratio is greater than 30 mg/mmol - total protein excretion exceeds 0.5 g/day Do not use eGFR in pregnancy. Consider thromboprophylaxis for proteinuria above 5 g/day (ratio greater than 220 mg/mmol). [1]
  • Offer: - a 20-week anomaly scan including the fetal heart (4 chambers, outflow tracts and 3 vessels) - ultrasound of fetal growth and amniotic fluid every 4 weeks from 28 to 36 weeks Routine fetal wellbeing monitoring before 38 weeks is not recommended unless there is a risk of growth restriction. [1]

Timing of birth and intrapartum care

  • Type 1 or type 2 diabetes: - without complications: advise elective birth (induction, or caesarean if indicated) between 37 weeks and 38 weeks plus 6 days - with complications: consider birth before 37 weeks Gestational diabetes: - advise birth by 40 weeks plus 6 days, offering elective birth if undelivered - with complications: consider earlier birth [1]
  • Check capillary glucose hourly in labour, keeping it between 4 and 7 mmol/litre. - Type 1 diabetes: consider IV dextrose-insulin infusion from established labour. - Any diabetes: use the infusion if glucose is not maintained in range. - General anaesthesia for the birth: monitor glucose every 30 minutes from induction of anaesthesia until after the baby is born and the woman is fully conscious. [1]

Neonatal care

  • Test the baby's glucose routinely at 2 to 4 hours after birth. Women with diabetes should feed their babies within 30 minutes, then every 2 to 3 hours until pre-feed capillary glucose stays at least 2.0 mmol/litre. Reserve tube feeding or IV dextrose for: - readings below 2.0 mmol/litre on 2 consecutive occasions despite maximal feeding support - abnormal clinical signs - ineffective oral feeding [1]

Postnatal care and follow-up

  • Immediately after birth: - insulin-treated pre-existing diabetes: reduce insulin and titrate to glucose readings - gestational diabetes: stop glucose-lowering therapy - breastfeeding women with type 2 diabetes: may resume or continue metformin (off-label) but should avoid other oral agents [1]
  • After gestational diabetes, test glucose before transfer to community care. If levels have normalised: - offer fasting plasma glucose at 6 to 13 weeks - after 13 weeks, offer fasting glucose, or HbA1c if fasting testing is not possible - do not routinely offer a 75-g 2-hour OGTT - offer annual HbA1c if postnatal testing is negative [1]
  • Interpreting a postnatal fasting plasma glucose: - Below 6.0 mmol/litre: low current probability of diabetes. Continue lifestyle advice and test annually. Counsel on moderate type 2 diabetes risk and offer prevention-guideline advice. - 6.0 to 6.9 mmol/litre: high risk of type 2 diabetes. Offer prevention-guideline advice and interventions. - 7.0 mmol/litre or above: likely type 2 diabetes. Offer a confirmatory test. [1]
  • Interpreting a postnatal HbA1c: - Below 39 mmol/mol (5.7%): low current probability of diabetes. Continue lifestyle advice and test annually. Counsel on moderate type 2 diabetes risk and offer prevention-guideline advice. - 39 to 47 mmol/mol (5.7% and 6.4%): high risk of type 2 diabetes. Offer prevention-guideline advice and interventions. - 48 mmol/mol (6.5%) or above: type 2 diabetes. Refer for further care. [1]

Limitations and use

  • The summary is based only on the clinical recommendations chapter. Research recommendations, rationale and impact, evidence reviews and update-history chapters were not reviewed.
  • Flowcharts and visual algorithms were available only as alternative text.
  • Several topics are delegated to other NICE guidelines and are not detailed here: - antiplatelet prophylaxis for pre-eclampsia (hypertension in pregnancy) - routine antenatal care - dietary advice (maternal and child nutrition) - type 2 diabetes prevention thresholds
  • NICE states it is assessing how the discontinuation of insulin detemir affects the long-acting insulin recommendation.
  • Recommendations reflect UK NHS service arrangements, such as joint diabetes–antenatal clinics and the NHS Diabetes Prevention Programme.
  • The summary condenses the guideline and omits some recommendations, including: - hypoglycaemia supplies, glucagon and insulin pump therapy - preterm labour management - neonatal admission criteria - detailed counselling content

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Diabetes in pregnancy: management from preconception to the postnatal period

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
25 February 2015
Publisher’s latest update
16 December 2020
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Preconception care
  • Gestational diabetes: risk assessment, testing and diagnosis
  • Gestational diabetes: treatment
  • Antenatal care for all women with diabetes
  • Timing of birth and intrapartum care
  • Neonatal care
  • Postnatal care and follow-up
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House